The goal of this consortium is to establish tools that can be used as biomarkers and/or sensitive and reliable objective assays of social impairment in autism spectrum disorder (ASD) clinical trials. The consortium will conduct a naturalistic, longitudinal study of preschool (3-5 years) and school aged (6-11 years) children with ASD and typical development (TD) with IQ ranging from 50-115. Children will be assessed across three time points (T1: Baseline, T2: 6 weeks, T3: 24 weeks) using clinician, caregiver and lab-based (LB) measures of social impairment, along with a battery of conceptually related EEG and ET tasks and independent ratings of clinical status. Five Collaborating Implementation Sites (?Sites?), all highly experienced in multi-site collaborative clinical research using the methodologies proposed here in children with TD and ASD, will contribute equally to data collection. The Data Coordinating Core (DCC) will provide a secure informatics infrastructure to streamline communication and data flow throughout the consortium to ensure organized, secure data management, quality control, and reliable upload to the National Database for Autism Research (NDAR) and NIH/NIMH Data Repositories. The Data Acquisition and Analysis Core (DAAC) will oversee consistent application of scientific standards and methodological rigor for data collection, processing, and analytics. The Administrative Core (Admin Core) will oversee the operations of the Sites, the DCC, and the DAAC to ensure methodologically and ethically rigorous, efficient completion of study aims and to coordinate with federal and private partners in this cooperative agreement.
The specific aims of the Admin Core are to: 1) Coordinate and streamline communication and data sharing among components of the consortium to manage all aspects of the Set up, Implementation and Data Analysis phases, including recruitment and data collection, data management and quality control, standardization of data acquisition and processing, analytic planning, financial management; 2) Administer the consortium project across all Sites and Cores in terms of managing the central IRB, developing and disseminating SOPs, implementing GCP, maintaining research fidelity, overseeing quality control, and planning timely upload to NIH/NIMH Data Repositories; 3) Maintain appropriate communication among the consortium members by integrating feedback from federal and private partners, executing the finalized protocol as per the collaborative agreement, bringing together consortium leaders and partners in Steering Committee Meetings, and convening meetings of the External Advisory Board.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19MH108206-01
Application #
8984980
Study Section
Special Emphasis Panel (ZMH1)
Project Start
Project End
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Kang, Erin; Keifer, Cara M; Levy, Emily J et al. (2018) Atypicality of the N170 Event-Related Potential in Autism Spectrum Disorder: A Meta-analysis. Biol Psychiatry Cogn Neurosci Neuroimaging 3:657-666
Webb, Sara Jane; Neuhaus, Emily; Faja, Susan (2017) Face perception and learning in autism spectrum disorders. Q J Exp Psychol (Hove) 70:970-986
McPartland, James C (2017) Developing Clinically Practicable Biomarkers for Autism Spectrum Disorder. J Autism Dev Disord 47:2935-2937
Tremblay, Sébastien; Sharika, K M; Platt, Michael L (2017) Social Decision-Making and the Brain: A Comparative Perspective. Trends Cogn Sci 21:265-276
Varcin, Kandice J; Jeste, Shafali S (2017) The emergence of autism spectrum disorder: insights gained from studies of brain and behaviour in high-risk infants. Curr Opin Psychiatry 30:85-91
Shic, Frederick (2016) Eye Tracking as a Behavioral Biomarker for Psychiatric Conditions: The Road Ahead. J Am Acad Child Adolesc Psychiatry 55:267-8
McPartland, James C (2016) Considerations in biomarker development for neurodevelopmental disorders. Curr Opin Neurol 29:118-22